Additionally, the 36-month beta value for MIST is 0.86. There are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 2 rating it as “overweight,” 2 rating it as “hold,” and 0 rating it as “sell.”
The public float for MIST is 50.89M and currently, short sellers hold a 5.34% ratio of that float. The average trading volume of MIST on May 09, 2025 was 2.58M shares.
MIST) stock’s latest price update
Milestone Pharmaceuticals Inc (NASDAQ: MIST)’s stock price has decreased by -6.98 compared to its previous closing price of 1.29. However, the company has seen a -9.09% decrease in its stock price over the last five trading sessions. seekingalpha.com reported 2025-04-04 that In March, we welcomed 30 new analysts to Seeking Alpha, and in this article we are showcasing their stock picks and investment strategies. Our analysts covered a diverse set of industries—including IT, financials, utilities, materials, and mining—and provided ratings ranging from Strong Sell to Strong Buy. Top picks include C3.ai, Robinhood, Central Puerto, CF Industries, and Kyndryl.
MIST’s Market Performance
Milestone Pharmaceuticals Inc (MIST) has experienced a -9.09% fall in stock performance for the past week, with a 83.80% rise in the past month, and a -45.21% drop in the past quarter. The volatility ratio for the week is 8.77%, and the volatility levels for the past 30 days are at 10.67% for MIST. The simple moving average for the past 20 days is 7.66% for MIST’s stock, with a -26.74% simple moving average for the past 200 days.
Analysts’ Opinion of MIST
Many brokerage firms have already submitted their reports for MIST stocks, with Rodman & Renshaw repeating the rating for MIST by listing it as a “Buy.” The predicted price for MIST in the upcoming period, according to Rodman & Renshaw is $9 based on the research report published on August 22, 2024 of the previous year 2024.
Jefferies, on the other hand, stated in their research note that they expect to see MIST reach a price target of $4, previously predicting the price at $8. The rating they have provided for MIST stocks is “Hold” according to the report published on June 20th, 2023.
Piper Sandler gave a rating of “Overweight” to MIST, setting the target price at $10 in the report published on April 22nd of the previous year.
MIST Trading at -14.34% from the 50-Day Moving Average
After a stumble in the market that brought MIST to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -56.36% of loss for the given period.
Volatility was left at 10.67%, however, over the last 30 days, the volatility rate increased by 8.77%, as shares surge +66.67% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -31.43% lower at present.
During the last 5 trading sessions, MIST fell by -9.09%, which changed the moving average for the period of 200-days by -21.05% in comparison to the 20-day moving average, which settled at $1.1147. In addition, Milestone Pharmaceuticals Inc saw -49.15% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for MIST
The total capital return value is set at -0.63. Equity return is now at value -277.55, with -55.09 for asset returns.
Based on Milestone Pharmaceuticals Inc (MIST), the company’s capital structure generated 0.81 points at debt to capital in total, while cash flow to debt ratio is standing at -0.52. The debt to equity ratio resting at 4.17. The interest coverage ratio of the stock is -11.78.
Currently, EBITDA for the company is -42.1 million with net debt to EBITDA at -0.75. The liquidity ratio also appears to be rather interesting for investors as it stands at 9.10.
Conclusion
In conclusion, Milestone Pharmaceuticals Inc (MIST) has seen bad performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
